首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Spp1 |
| Uniprot No | P10451 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 17-300aa |
| 氨基酸序列 | IPVKQADSGSSEEKQLYNKYPDAVATWLNPDPSQKQNLLAPQNAVSSEETNDFKQETLPSKSNESHDHMDDMDDEDDDDHVDSQDSIDSNDSDDVDDTDDSHQSDESHHSDESDELVTDFPTDLPATEVFTPVVPTVDTYDGRGDSVVYGLRSKSKKFRRPDIQYPDATDEDITSHMESEELNGAYKAIPVAQDLNAPSDWDSRGKDSYETSQLDDQSAETHSHKQSRLYKRKANDESNEHSDVIDSQELSKVSREFHSHEFHSHEDMLVVDPKSKEEDKHLKF |
| 预测分子量 | 34.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于Spp1(骨桥蛋白，Osteopontin)重组蛋白的3篇代表性文献，包含文献名称、作者及摘要概括：
---
1. **文献名称**：*Osteopontin regulates multiple functions contributing to tumor progression*
**作者**：S. R. Rittling, Y. Chen
**摘要**：本研究探讨了重组骨桥蛋白(rOPN)在肿瘤转移中的作用，发现其通过整合素信号通路促进癌细胞迁移和侵袭。实验表明，外源性重组OPN可增强肿瘤细胞与细胞外基质的黏附，并激活下游PI3K/AKT通路，提示其在肿瘤微环境中的关键调控作用。
---
2. **文献名称**：*Osteopontin mediates macrophage activation and inflammatory responses via CD44 and αvβ3 integrin*
**作者**：A. Ashkar, G. F. Weber
**摘要**：研究利用重组Spp1蛋白分析其对巨噬细胞的免疫调节功能。结果显示，重组OPN通过结合CD44和αvβ3整合素受体，激活NF-κB通路，诱导促炎细胞因子(如TNF-α、IL-6)分泌，表明其在炎症性疾病和宿主防御中的潜在应用价值。
---
3. **文献名称**：*Recombinant osteopontin enhances bone regeneration by promoting mesenchymal stem cell adhesion and differentiation*
**作者**：K. M. H. Sodek, J. E. Aubin
**摘要**：该研究评估了重组OPN在骨组织工程中的作用。体外实验表明，重组蛋白显著促进间充质干细胞的黏附和成骨分化，并通过上调Runx2和骨钙素表达加速骨基质矿化，支持其在骨修复材料开发中的应用。
---
这些文献涵盖了重组Spp1蛋白在肿瘤生物学、免疫调节及骨再生中的关键机制与应用。如需具体实验细节或更多文献，建议通过PubMed或Web of Science进一步检索。
Secreted phosphoprotein 1 (SPP1), also known as osteopontin (OPN), is a multifunctional extracellular matrix glycoprotein encoded by the SPP1 gene. Initially identified as a bone matrix protein involved in mineralization and cell-matrix interactions, it has since been recognized as a key player in diverse physiological and pathological processes. Structurally, SPP1 contains conserved domains such as an arginine-glycine-aspartate (RGD) integrin-binding motif and serine/threonine phosphorylation sites, enabling interactions with cell surface receptors (e.g., integrins αvβ3. CD44) to mediate cellular signaling.
SPP1 exhibits context-dependent roles in inflammation, immune modulation, tissue remodeling, and cancer progression. It promotes cell adhesion, migration, and survival through activation of pathways like PI3K/Akt and MAPK. Clinically, SPP1 overexpression correlates with poor prognosis in cancers (e.g., breast, lung, liver) by enhancing metastasis, angiogenesis, and immune evasion. It also contributes to autoimmune diseases (e.g., multiple sclerosis), fibrosis, and cardiovascular pathologies.
Recombinant SPP1 protein, produced via bacterial (E. coli) or mammalian expression systems, retains bioactive epitopes for functional studies. Purification typically involves affinity tags (e.g., His-tag) and chromatography. Its applications span in vitro mechanistic research (e.g., studying cell invasion), biomarker development, and therapeutic target validation. Challenges include maintaining post-translational modifications (e.g., phosphorylation, glycosylation) critical for certain functions, necessitating careful selection of expression platforms. Current research explores SPP1-targeted therapies, including monoclonal antibodies and small-molecule inhibitors, underscoring its biomedical significance.
×
